Filing Flows › Health Care › Amneal Pharmaceuticals (AMRX)
Amneal Pharmaceuticals (AMRX) earnings and revenue breakdown
Latest: Q3 2026 · 8-K filed Nov 3, 2026
Q3 2026 Revenue up 10% year over year to $863M · 1¢ of every $1 of revenue kept as net profit · operating margin 11.1%
Amneal Pharmaceuticals made $863M in Q3 2026 (+10% Y/Y). Operating margin 11.1%, net earnings $12.3M. See where every dollar goes — costs, profit and cash — as a Sankey from the 8-K filed Nov 3, 2026 (preliminary, from the earnings release).
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $862.7M in Q3 2026, up 10% year over year and up 8% from the previous quarter.
Gross margin was 38.7%, up 3.8 points from Q3 2025. Operating profit was $95.4M, a 11.1% margin (up 2.1 points year over year). Of the extra revenue versus Q3 2025, 32% reached operating profit, above the 9% margin then. Operating expenses grew 17% against revenue growth of 10%. The fastest-growing cost line was Other operating costs (+1146%). Net earnings were −$7.5M. The effective tax rate was 18.3%.
Operating cash flow was $98.3M (down 17% year over year), 799% of net income including minority interests. Non-cash charges added back $10.5M of share-based compensation. Working capital and other items added $75.5M. Capital expenditures of $31.8M left free cash flow of $66.5M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 8-K | Nov 3, 2026 | $863M | +10% | 11.1% | $12.3M | $98.3M |
| Q2 2026 | 10-Q | Aug 6, 2026 | $796M | +10% | 16.3% | $57.7M | −$21.2M |
| Q1 2026 | 10-Q | May 7, 2026 | $723M | +4% | 19.6% | $62.3M | −$26.7M |
| Q4 2025 | 10-K | Feb 27, 2026 | $814M | +12% | 13.8% | $35.1M | $130M |
| Q3 2025 | 10-Q | Nov 6, 2025 | $785M | +12% | 9.0% | $18.1M | $118M |
| Q2 2025 | 10-Q | Aug 7, 2025 | $725M | +3% | 15.4% | $22.4M | $83.8M |
| Q1 2025 | 10-Q | May 7, 2025 | $695M | +6% | 14.4% | $12.2M | $7.4M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
Customers and suppliers named in filings
Sells to
- CVS · Stated in 10-K (named, share not stated) · source
- COR · Stated in 10-K (named, share not stated) · source
- MCK · Stated in 10-K (named, share not stated) · source
- CAH · Stated in 10-K (named, share not stated) · source
About Amneal Pharmaceuticals
Amneal Pharmaceuticals, Inc. (the “Company”, “we,” “us,” or “our”) is a diversified, global biopharmaceutical company that develops, manufactures, markets, and distributes a diverse portfolio of essential medicines. Our Affordable Medicines segment includes retail generics, injectables, and biosimilars. In our Specialty segment, we offer a portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders. Through our AvKARE segment, we are a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. We operate principally in the United States (“U.S.”), India, and Ireland. Refer to the section “Segments of the Business” below for an overview of our segments.
In its own words, from its 10-K, filed Feb 27, 2026.
Amneal Pharmaceuticals against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +10% against the peers' median +10%. Operating margin: 11.1% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| AMRX Amneal Pharmaceuticals | Q3 2026 | $863M | +10% | 11.1% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Amneal Pharmaceuticals 8-K on SEC EDGAR · CIK 1723128 · Pharmaceutical Preparations
Guidance and outlook
13F: who owns AMRX and who is buying
More on AMRX
- How Amneal Pharmaceuticals makes money: revenue by segment
- Amneal Pharmaceuticals next earnings date and what analysts expect
- Amneal Pharmaceuticals stock forecast, price target and fair value
- Who owns Amneal Pharmaceuticals stock: holders, funds and Congress trades
- Amneal Pharmaceuticals guidance and outlook
- Is Amneal Pharmaceuticals a takeover target? LBO and rumors
- Amneal Pharmaceuticals recalls, complaints and regulation
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results
- Amneal Pharmaceuticals guidance history: guided vs reported
- Amneal Pharmaceuticals gross margin by quarter
- Amneal Pharmaceuticals operating margin by quarter
- Amneal Pharmaceuticals net income by quarter
- Amneal Pharmaceuticals free cash flow by quarter
- Amneal Pharmaceuticals R&D spending by quarter
- Amneal Pharmaceuticals capital expenditures by quarter